Hsbc Holdings PLC Buys 12,691 Shares of UiPath Inc. (NYSE:PATH)

Hsbc Holdings PLC boosted its stake in UiPath Inc. (NYSE:PATHFree Report) by 14.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 98,725 shares of the healthcare company’s stock after acquiring an additional 12,691 shares during the period. Hsbc Holdings PLC’s holdings in UiPath were worth $2,455,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Intech Investment Management LLC lifted its stake in UiPath by 3.1% in the fourth quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after buying an additional 426 shares during the period. 180 Wealth Advisors LLC lifted its stake in UiPath by 0.3% in the fourth quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock valued at $4,497,000 after buying an additional 492 shares during the period. Bleakley Financial Group LLC lifted its stake in UiPath by 4.9% in the fourth quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after buying an additional 598 shares during the period. Simplicity Solutions LLC lifted its stake in UiPath by 4.9% in the fourth quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after buying an additional 598 shares during the period. Finally, Axxcess Wealth Management LLC lifted its stake in UiPath by 2.6% in the third quarter. Axxcess Wealth Management LLC now owns 29,121 shares of the healthcare company’s stock valued at $498,000 after buying an additional 740 shares during the period. 62.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the sale, the chief financial officer now owns 87,505 shares of the company’s stock, valued at approximately $1,998,614.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 96,000 shares of company stock valued at $2,023,440. Corporate insiders own 22.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on PATH shares. BMO Capital Markets lowered their target price on UiPath from $28.00 to $14.00 and set a “market perform” rating on the stock in a research report on Monday. Barclays lowered their target price on UiPath from $25.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 30th. Morgan Stanley lowered their target price on UiPath from $25.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 30th. Canaccord Genuity Group lowered their target price on UiPath from $30.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, May 31st. Finally, JPMorgan Chase & Co. lowered their target price on UiPath from $28.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, May 30th. Sixteen equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, UiPath has an average rating of “Hold” and an average target price of $18.12.

Get Our Latest Report on PATH

UiPath Stock Performance

PATH stock opened at $12.25 on Friday. The company has a market capitalization of $6.97 billion, a price-to-earnings ratio of -76.56 and a beta of 0.85. UiPath Inc. has a fifty-two week low of $11.53 and a fifty-two week high of $27.87. The stock has a fifty day moving average of $19.05 and a 200-day moving average of $21.85.

UiPath (NYSE:PATHGet Free Report) last issued its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. The business had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. UiPath had a negative return on equity of 2.97% and a negative net margin of 6.41%. Equities analysts predict that UiPath Inc. will post -0.2 EPS for the current year.

UiPath Company Profile

(Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

See Also

Want to see what other hedge funds are holding PATH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UiPath Inc. (NYSE:PATHFree Report).

Institutional Ownership by Quarter for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.